Libtayo sBLA granted FDA priority review in 2L recurrent or metastatic cervical cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FDA accepted for priority review the supplemental Biologics License Application for PD-1 inhibitor Libtayo (cemiplimab-rwlc), a monoclonal antibody, to treat patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login